| Literature DB >> 25801496 |
Koushik Tripathy1, Yog Raj Sharma, Karthikeya R, Rohan Chawla, Varun Gogia, Subodh Kumar Singh, Pradeep Venkatesh, Rajpal Vohra.
Abstract
Diabetic macular edema (DME) is the leading cause of moderate vision loss in diabetics. Modalities to image and monitor DME have evolved much in the last decade. Systemic control is the most important part of management. Available ocular management options include intravitreal antivascular endothelial growth factor (anti-VEGF) agents, laser, steroids (intravitreal or peribulbar), vitrectomy, topical medications and others. Anti-VEGF agents are increasingly being used in clinical practice with good clinical response and are currently the preferred mode of treatment worldwide.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25801496 DOI: 10.2174/1573399811999150324120640
Source DB: PubMed Journal: Curr Diabetes Rev ISSN: 1573-3998